An announcement from Tempest Therapeutics ( (TPST) ) is now available.
On August 8, 2025, Tempest Therapeutics, Inc. repaid $3.5 million to fully satisfy its obligations under a Loan and Security Agreement with Oxford Finance LLC, effectively terminating the agreement and releasing all associated liens and security interests. Earlier, on April 9, 2025, the company announced plans to explore strategic alternatives, including potential mergers or partnerships, to advance its clinical-stage programs and enhance stockholder value, particularly focusing on its promising oncology assets such as amezalpat and TPST-1495.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.
Tempest Therapeutics faces typical challenges for a biotech firm in its early stages, with no revenue and high R&D expenses leading to financial losses. While there are signs of financial improvement, the stock’s bearish trend and high volatility pose risks. The negative P/E ratio highlights unprofitability, with no dividend yield as the company focuses on growth.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company based in Brisbane, California, focused on developing small molecule therapeutics with tumor-targeted and immune-mediated mechanisms to treat various types of cancer.
YTD Price Performance: -39.76%
Average Trading Volume: 755,179
Technical Sentiment Signal: Strong Buy
Current Market Cap: $23.01M
See more insights into TPST stock on TipRanks’ Stock Analysis page.